Tanisha Carino
Showing 1–6 of 6 transcripts.
- Milken Institute1h 22m
Toward a Healthier Future
Will Durant, Mike Milken, Tanisha Carino, Michael Milken, Francis Collins, Susan Desmond-Hellmann, Bernard J. Tyson, Seema Verma, Sue Desmond-Hellman
Representatives from the Gates Foundation, Kaiser Permanente, CMS, and NIH converged to outline a unified strategy shifting global health systems from reactive treatment toward proactive prevention and precision medicine. Leaders highlighted specific breakthroughs in gene therapy, AI-driven neural decoding, and data interoperability while proposing structural reforms to align financial incentives with long-term population wellness and disease eradication. The consensus among these major institutions emphasizes that future economic prosperity and reduced healthcare costs depend on integrating community infrastructure, digital infrastructure, and innovative financing models to address challenges ranging from mental health crises to rare genetic disorders.
- Milken Institute1h 1m
World-class Healthcare: Investing in Biomedical Innovation
Tanisha Carino, Christopher Hite, Bryan Johnson, Sean Parker, D.A. Wallach
Moderated by Dr. Tanisha Carino in Abu Dhabi, this session analyzed the convergence of global biomedical innovation and market dynamics, highlighted by the historic $92 billion Bristol-Myers Squibb acquisition of Celgene as a catalyst for pipeline stability. The discussion detailed how falling hard science costs and platforms like Ginkgo Bioworks are compressing development timelines, while investment strategies increasingly favor foundational tools over singular disease treatments to address the translational gap between academic research and commercial viability. Despite concerns regarding venture capital concentration in oncology and systemic US healthcare incentives, the event projected that long-term pricing decreases and extended lifespans could emerge from global regulatory evolution and the integration of AI-driven data collection.
- Milken Institute56 min
Asia's Next Frontier: Building Capabilities for Translational Research
Tanisha Carino, Christiana Bardon, Carl Firth, Annalisa Jenkins, Baiju Shah, Chris Bardone
Faster Cures and Milken Institute convene Asian policymakers and industry leaders to address the critical "Valley of Death" separating basic science from clinical cures across the region's rapidly expanding R&D landscape. The discussion highlights Singapore's strategic shift toward translational funding and data infrastructure, China's accelerated regulatory reforms, and the Harrington Project's hybrid model designed to bridge skill and capital gaps for high-burden diseases. While genomic initiatives and reimbursement changes promise to modernize access, the session concludes that overcoming cultural barriers in patient advocacy and workforce specialization remains essential for translating scientific knowledge into effective patient treatments.
- Milken Institute34 min
A Conversation with Scott Gottlieb, Commissioner, U.S. Food and Drug Administration
Scott Gottlieb, Tanisha Carino, Michael Milken
The FDA is implementing a comprehensive strategic shift to accelerate drug approvals through digital health integration, organizational restructuring within the Office of New Drugs, and a transition to risk-based, post-market regulation for digital tools and manufacturing. This initiative aims to increase review productivity by 20%, publish hundreds of new guidances, and release detailed approval memos within 48 hours to enhance transparency while addressing pipeline disparities in rare versus common diseases. Concurrently, the agency prioritizes tobacco control through modified risk products and fosters market competition to lower drug costs, with Commissioner Gottlieb warning that ossified reimbursement models for novel therapies threaten future innovation if not adapted.
- Milken Institute1h 2m
Paying for Cures
Colleen Rye, Christiana Bardon, Louis DeGennaro, Joe La Barge, Mark Trusheim, Cynthia Verst, Cindy Virst, Mark Trusseimer, Chris Barden, Joe Medina, Eric Schmidt, Lou, Louis Kombolaini, John McWhorter, Tanisha Carino, Martha Minowski
Discussions on the evolution of curative gene therapies analyze the projected surge of over 500 pipeline candidates and the necessary shift from chronic treatment models to one-time cures that disrupt traditional pricing structures. Industry experts highlight innovative financial mechanisms, including outcomes-based rebates and installment payments, designed to navigate complex regulatory hurdles like Medicaid best price rules and FASB accounting volatility while addressing manufacturing costs. Despite significant challenges in social equity and international reimbursement disparities, the consensus suggests that historical precedents and market-driven competition will ultimately sustain a system capable of integrating these high-cost, durable medical breakthroughs.
- Milken Institute1h 12m
The Future of Health 2018
Tanisha Carino, Francis Collins, Diana DeGette, Jim Yong Kim, Michael Milken, Rajiv Shah
At a recent biomedical and economic conference, leaders discussed the transformative $3 billion 21st Century Cures Act and the ambitious "All of Us" program, which aims to recruit one million participants to generate personalized genomic and health data while addressing the opioid crisis through standardized research. Complementing these health initiatives, the World Bank introduced a Human Capital Index to rank nations on health and education outcomes, urging G20 leaders and investors to fund early development and infrastructure to mitigate global risks like automation-driven inequality and obesity-related economic burdens. These strategies collectively emphasize that sustained economic growth and stability depend on treating human capital investment as a critical driver of national sovereignty and future market resilience.